GeoVax CEO David Dodd to Discuss MVA-Based Vaccine Platforms for Broader Infectious Disease Preparedness in Tribe Public Webinar
GeoVax Labs CEO David Dodd will participate in a Tribe Public webinar on May 28, 2026, to discuss the need for platform-based vaccine technologies to address multiple viral threats like Ebola, Marburg, mpox, and hantavirus, emphasizing the limitations of single-threat preparedness.
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced that Chairman and Chief Executive Officer David Dodd will participate in Tribe Public's CEO Presentation and Q&A Webinar Event titled “Ebola, Marburg, Hantavirus, Mpox and Beyond: Building a Resilient Infectious Disease Preparedness Strategy.” The webinar is scheduled for Thursday, May 28, 2026, at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time.
The event comes amid ongoing concerns about emerging viral threats, including recent hantavirus cases, and underscores the critical need for a more robust and adaptable global biodefense infrastructure. According to a press release, Dodd will discuss why preparedness against one viral threat does not necessarily ensure preparedness against the next, and how GeoVax's MVA-based vaccine technologies could play a role in addressing these gaps.
“Ebola, Marburg, Mpox and most recently Hantavirus concerns all reinforce the same lesson: global preparedness strategies must evolve beyond reactive, single-threat approaches,” said David Dodd, Chairman and CEO of GeoVax. “GeoVax is focused on advancing versatile MVA-based vaccine technologies designed to support broader infectious disease preparedness and help address critical gaps in domestic and global biodefense infrastructure.”
The webinar discussion is expected to address the growing importance of platform-based vaccine technologies, why emerging outbreaks continue to expose vulnerabilities in global response infrastructure, the potential applicability of MVA-based technologies across multiple viral threats—including orthopox and hemorrhagic fever viruses—and the importance of scalable and resilient domestic vaccine manufacturing capabilities.
GeoVax's priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. This highlights the company's commitment to developing versatile platforms that can be adapted to multiple threats, rather than focusing on a single pathogen.
The event will be hosted by Tribe Public Managing Member John F. Heerdink, Jr., and participants can register for the complimentary Zoom webinar at Ebola-May-2026.TribePublic.com. Questions may be submitted in advance to Tribe Public or during the live session.
The implications of this announcement are significant for the biodefense and infectious disease preparedness landscape. As the world has witnessed with COVID-19, mpox, and other outbreaks, reactive approaches that focus on single threats can leave populations vulnerable to emerging or re-emerging pathogens. Platform-based technologies like MVA offer the potential for rapid adaptation to new threats, which could dramatically improve response times and manufacturing scalability. For investors and public health officials, GeoVax's strategy represents a shift toward a more sustainable and resilient preparedness model—one that could reduce the economic and human costs of future pandemics.